Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Valneva Soars as Covid Vaccine Candidate Shows Promise

Published 10/18/2021, 05:28 AM
Updated 10/18/2021, 05:31 AM
© Reuters

© Reuters

By Dhirendra Tripathi

Investing.com – ADRs of Valneva (NASDAQ:VALN) climbed more than 31% in Monday’s premarket as the company said the phase-3 trials of a prospective vaccine against Covid-19 vaccine had shown positive results.

The trials pitted Valneva’s candidate against the AstraZeneca (NASDAQ:AZN) vaccine that is among the six most widely used in the world against Covid. Valneva claims the results showed its candidate has superior neutralizing antibody levels compared to the British firm’s vaccine.

The outcome may suggest that both vaccines used in the study prevented severe Covid-19 caused by the circulating variants including the predominant Delta, Valneva said.

Valneva said it is preparing for trials in children 5-12 and a booster trial to evaluate the vaccine, VLA2001’s, booster performance for people in need of it.

The company has commenced submission for initial approval with the UK’s Medicines and Healthcare products Regulatory Agency and is preparing to initiate the same with the European Medicines Agency.

The announcement comes only weeks after the U.K. cancelled a provisional order of 100 million doses of the drug alleging that the company had violated its contract. Valneva had denied the allegations at the time and outside observers had seen the move as motivated in part by friction between the U.K. and French government over mutual implementation of the Brexit agreement and a bilateral agreement on policing migrant flows across the English Channel.

The stock had lost more than half its value in reaction to the U.K.'s move, but has now around half of those losses.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.